A G protein-coupled, IP3/protein kinase C pathway controlling the synthesis of phosphaturic hormone FGF23 by He, Qing et al.
A G protein–coupled, IP3/protein kinase C
pathway controlling the synthesis of
phosphaturic hormone FGF23
Qing He, … , Paola Divieti Pajevic, Murat Bastepe
JCI Insight. 2019;4(17):e125007. https://doi.org/10.1172/jci.insight.125007.
  
Dysregulated actions of bone-derived phosphaturic hormone fibroblast growth factor 23
(FGF23) result in several inherited diseases, such as X-linked hypophosphatemia (XLH),
and contribute substantially to the mortality in kidney failure. Mechanisms governing FGF23
production are poorly defined. We herein found that ablation of the Gq/11a–like, extralarge
Ga subunit (XLas), a product of GNAS, exhibits FGF23 deficiency and hyperphosphatemia
in early postnatal mice (XLKO). FGF23 elevation in response to parathyroid hormone, a
stimulator of FGF23 production via cAMP, was intact in XLKO mice, while skeletal levels of
protein kinase C isoforms a and d (PKCa and PKCd) were diminished. XLas ablation in
osteocyte-like Ocy454 cells suppressed the levels of FGF23 mRNA, inositol 1,4,5-
trisphosphate (IP3), and PKCa/PKCd proteins. PKC activation in vivo via injecting phorbol
myristate acetate (PMA) or by constitutively active Gqa-Q209L in osteocytes and
osteoblasts promoted FGF23 production. Molecular studies showed that the PKC
activation–induced FGF23 elevation was dependent on MAPK signaling. The baseline
PKC activity was elevated in bones of Hyp mice, a model of XLH. XLas ablation
significantly, but modestly, reduced serum FGF23 and elevated serum phosphate in Hyp
mice. These findings reveal a potentially hitherto-unknown mechanism of FGF23 synthesis
involving a G protein–coupled IP3/PKC pathway, which may be targeted to fine-tune FGF23
levels.
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Introduction
Phosphate is necessary for cell metabolism and growth, as well as skeletal development and mineraliza-
tion, and excess levels of  phosphate can lead to soft tissue mineralization (1–5). Fibroblast growth factor 
23 (FGF23) is a polypeptide hormone that acts on kidneys to stimulate urinary phosphate excretion and to 
inhibit the generation of  the bioactive vitamin D metabolite, 1,25 dihydroxyvitamin D [1,25(OH)2D] (6, 7). 
FGF23 deficiency or impaired FGF23 action results in increased levels of  serum phosphate, 1,25(OH)2D, 
and calcium, thus causing increased tendency of  soft tissue mineralization, as seen in certain forms of  
tumoral calcinosis. Conversely, excess production of  FGF23 leads to renal phosphate wasting and hypo-
phosphatemia with inappropriately suppressed levels of  1,25(OH)2D, as seen in tumor-induced osteoma-
lacia and several inherited disorders of  hypophosphatemia, such as X-linked hypophosphatemic rickets. 
FGF23 production also increases markedly in iron deficiency, driving the hypophosphatemia in patients 
with autosomal dominant hypophosphatemic rickets. In addition, the progressive increase of  FGF23 in 
renal failure disrupts vitamin D metabolism, contributes to secondary hyperparathyroidism, and leads to 
impaired bone mineralization. Moreover, FGF23 elevation is directly associated with cardiovascular mor-
tality seen in patients with chronic kidney disease. Recently, high circulating levels of  FGF23 have also 
been associated with increased risk of  dementia and Alzheimer’s disease (8).
FGF23 is mainly synthesized by mature osteoblasts and osteocytes in bone (9, 10), but the molecular mech-
anisms and signaling pathways governing FGF23 production remain poorly understood. Several stimulators of  
Dysregulated actions of bone-derived phosphaturic hormone fibroblast growth factor 23 (FGF23) 
result in several inherited diseases, such as X-linked hypophosphatemia (XLH), and contribute 
substantially to the mortality in kidney failure. Mechanisms governing FGF23 production are poorly 
defined. We herein found that ablation of the Gq/11α–like, extralarge Gα subunit (XLαs), a product 
of GNAS, exhibits FGF23 deficiency and hyperphosphatemia in early postnatal mice (XLKO). FGF23 
elevation in response to parathyroid hormone, a stimulator of FGF23 production via cAMP, was 
intact in XLKO mice, while skeletal levels of protein kinase C isoforms α and δ (PKCα and PKCδ) 
were diminished. XLαs ablation in osteocyte-like Ocy454 cells suppressed the levels of FGF23 
mRNA, inositol 1,4,5-trisphosphate (IP3), and PKCα/PKCδ proteins. PKC activation in vivo via 
injecting phorbol myristate acetate (PMA) or by constitutively active Gqα-Q209L in osteocytes 
and osteoblasts promoted FGF23 production. Molecular studies showed that the PKC activation–
induced FGF23 elevation was dependent on MAPK signaling. The baseline PKC activity was elevated 
in bones of Hyp mice, a model of XLH. XLαs ablation significantly, but modestly, reduced serum 
FGF23 and elevated serum phosphate in Hyp mice. These findings reveal a potentially hitherto-
unknown mechanism of FGF23 synthesis involving a G protein–coupled IP3/PKC pathway, which 
may be targeted to fine-tune FGF23 levels.
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FGF23 production have been identified, including dietary phosphorous, 1,25(OH)2D, inflammatory cytokines, 
calcium, and iron deficiency (1–5, 11). In addition, skeletal production of FGF23 is also induced by FGF recep-
tor 1 (FGFR1) signaling that primarily involves activation of the MAPK pathway (12–14). Another stimulator 
of FGF23 production is parathyroid hormone (PTH) (15–18). The receptor for PTH (PTH1R) is a G protein–
coupled receptor (GPCR), which couples to multiple heterotrimeric G proteins. The direct stimulatory action 
of PTH on FGF23 production, however, is mediated by the α subunit of the stimulatory G protein (Gsα), thus 
involving cAMP generation.
Gsα is derived from the GNAS complex gene, which also gives rise to the extralarge Gα subunit (XLαs) 
(19). XLαs uses a distinct, paternally active promoter and is partly identical to Gsα, diverging from the lat-
ter in its N-terminal region (20, 21). When overexpressed in cells or in mice, XLαs mimics Gsα with respect 
to cAMP generation both basally and in response to activation of  GPCRs, including PTH1R (22–24). Inter-
estingly, XLαs, despite sharing marked identity with Gsα, can mimic or enhance signaling of  Gq/11α, anoth-
er class of  heterotrimeric Gα subunits, which stimulate phospholipase C and, thereby, trigger generation 
of  inositol 1,4,5-trisphosphate (IP3) and diacylglycerol and the activation of  protein kinase C (PKC) (25). 
XLαs is expressed in a wide range of  tissues, including cells of  the osteoblast lineage (26–28). In this study, 
we addressed whether FGF23 production is regulated by the cellular action of  XLαs. We found that XLαs 
mediates FGF23 production in a cell-autonomous manner via the activation of  PKC signaling. Our addi-
tional investigations using different mouse models and cell culture experiments showed that PKC activation 
is critically involved in FGF23 production, integrating signals from different intracellular pathways. We 
also revealed elevated PKC activity in the skeletal tissue of  Hyp mice, a model of  X-linked hypophospha-
temia (XLH), and partially rescued the FGF23 and phosphate phenotype of  those mice by ablating XLαs.
Results
Serum FGF23 levels are significantly reduced in P10 XLαs-knockout mice, with resultant increase in serum phosphate 
and 1,25(OH)2D levels. Serum phosphate levels have been found to be elevated in some pediatric patients with 
paternal GNAS defects and in 10-day-old XLαs-knockout (XLKO) pups (29–36). We found that, at this age, 
XLKO pups were indeed hyperphosphatemic and, additionally, displayed modest hypocalcemia with only 
slightly elevated PTH levels that were not significantly different from the levels in WT littermates (Figure 
1, A–C). In addition, both C-terminal and intact FGF23 levels were significantly reduced in XLKO mice at 
postnatal day 10 (P10) (Figure 1, D and E). Similarly, XLKO mice also had modestly reduced C-terminal 
FGF23 levels at 4 weeks and 2 months of  age, compared with WT littermates, although the difference did not 
reach statistical significance (Supplemental Figure 1, A and B; supplemental material available online with 
this article; https://doi.org/10.1172/jci.insight.125007DS1). Moreover, serum level of  1,25(OH)2D, whose 
synthesis is known to be suppressed by FGF23, was markedly increased in XLKO mice (Figure 1F). Quanti-
tative reverse transcription PCR (qRT-PCR) analysis on total RNA isolated from P10 WT and XLKO femurs 
revealed that FGF23 mRNA levels in XLKO bone were less than 40% of the levels in WT bone (Figure 1G). 
The expression levels of  Phex and Dmp1, 2 genes in which inactivating mutations cause FGF23 excess and 
hypophosphatemic rickets, were also diminished in XLKO bones (Supplemental Figure 1C). 1,25(OH)2D 
level is controlled mainly by activities of  the renal enzymes 25-hydroxyvitamin D 1α-hydroxylase (Cyp27b1), 
which synthesizes 1,25(OH)2D, and 25-hydroxyvitamin D 24-hydroxylase (Cyp24a1), which metabolizes 
1,25(OH)2D. We found that the abundance of  Cyp27b1 mRNA was increased over 2.7-fold, while the expres-
sion of  Cyp24a1 mRNA was increased 1.8-fold in P10 XLKO kidneys compared with WT (Figure 1H), 
implying that the increased 1,25(OH)2D levels may reflect enhanced synthesis. FGF23 acts to decrease the 
abundance of  type II sodium-dependent phosphate cotransporter Npt2a in the renal brush border membrane. 
Western blots showed that the protein abundance of  Npt2a in XLKO renal brush border membrane was 
markedly increased (Figure 1, I and J). Immunofluorescence staining of  kidney sections from P10 WT and 
XLKO mice also showed a pronounced increase in Npt2a staining in XLKO (Figure 1K), consistent with the 
hyperphosphatemia in XLKO pups.
Recombinant FGF23 injection rescues hyperphosphatemia in XLKO mice. To address whether the phenotype 
of  XLKO mice resulted from reduced FGF23 levels, WT and XLKO mice were injected i.p. twice daily for 
4 days with vehicle or full-length FGF23 harboring mutations responsible for autosomal dominant hypo-
phosphatemic rickets (FGF23R176Q/R179Q); these mutations inhibit proteolytic inactivation of  FGF23. Upon 
FGF23R176Q/R179Q administration, the serum phosphate levels declined significantly in both WT and XLKO 
mice, and the elevated phosphate levels in XLKO mice were normalized to the levels in vehicle-injected 
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WT mice (Figure 2A). The blood ionized calcium levels in WT mice were significantly decreased upon 
FGF23 injection. On the other hand, the calcium level was surprisingly elevated and corrected to normal 
in XLKO mice by FGF23 administration, suggesting that the decreased calcium level observed in XLKO 
mice may be secondary to the elevated phosphate level (Figure 2B). Moreover, WT mice displayed the 
expected decrease in Cyp27b1 mRNA and the increase in Cyp24a1 mRNA expression, as measured by 
qRT-PCR (Figure 2, C and D). On the other hand, there was a more dramatic response to FGF23 in XLKO 
mice. Cyp27b1 mRNA levels were repressed over 90% in XLKO mice, and Cyp24a1 mRNA levels were 
induced by approximately 3.5-fold (Figure 2, C and D), predicting a decline of  the elevated 1,25(OH)2D 
levels in XLKO mice. These results demonstrated that the phosphate and vitamin D phenotype in XLKO 
mice results from FGF23 deficiency.
XLαs ablation does not impair PTH-induced FGF23 production or cAMP generation but dampens IP3 and 
PKC levels in osteocytes. PTH stimulates FGF23 production via a Gsα/cAMP–mediated mechanism 
(15–17), and PTH1R has been shown to couple to XLαs (22, 23). Injection with human PTH (aa 1–34) 
(50 nmol/kg) significantly augmented serum C-terminal FGF23 levels in both WT and XLKO pups 
after 2 hours, and the levels were comparable between the 2 genotypes (Figure 3A). Skeletal FGF23 
Figure 1. XLKO mice display decreased FGF23 levels with consequent alterations in phosphate and vitamin D metab-
olism. (A–F) Serum parameters of WT and KO mice at P10, including (A) phosphate, (B) blood ionized calcium, (C) PTH, 
(D) C-terminal FGF23, (E) intact FGF23, and (F) 1,25(OH)2D levels. (G) FGF23 mRNA levels in femurs and (H) Cyp27b1 and 
Cyp24a1 mRNA levels in renal tissue from P10 KO and WT mice. Data are shown as mean ± SEM of littermates from 3 
independent litters (n = 12 mice per group). (I) Western blot of Npt2a protein in renal brush border membrane samples 
from P10 KO and WT. Villin was used as a loading control. The blot is a representative of 3 independent experiments. (J) 
Densitometric quantification of renal brush border Npt2a protein from the Western blot experiments shown in panel 
I. (K) Npt2a and DAPI immunostaining of kidney sections from P10 XLKO and WT mice. *P < 0.05, **P < 0.01, and NS, 
not significant, calculated by unpaired, 2-tailed Student’s t test.
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mRNA expression was also significantly increased upon 2 hours of  PTH treatment in both WT and 
XLKO mice, with no evidence of  impaired PTH-induced FGF23 production in XLKO (Figure 3B). 
XLαs, like Gαs, can stimulate generation of  the second messenger cAMP. We thus examined the cAMP 
levels in Ocy454 cells, an osteocyte-like cell line (37), in which we have previously ablated XLαs by 
using CRISPR/Cas9 (38). Both the basal and PTH-induced levels of  cAMP were higher in XLKO 
Ocy454 cells than in control cells (Supplemental Figure 2A). These enhanced cAMP levels in XLKO 
cells are consistent with our previous finding that Gsα protein level is moderately elevated in XLKO 
Ocy454 cells (38). We have previously demonstrated that ablation of  XLαs represses IP3 generation 
and the total levels of  several PKC isoforms, including PKCα and PKCδ, in renal proximal tubules 
(25). Similarly, the analysis of  P10 XLKO femur samples revealed reduced levels of  PKCα and PKCδ 
(Figure 3, C and D). As expected, XLαs expression was undetectable in XLKO femurs, while Gsα 
expression appeared moderately increased (Figure 3C). Consistent with our in vivo results, FGF23 
mRNA levels, as well as PKCα and PKCδ protein levels, were markedly reduced in XLKO Ocy454 
cells (Figure 3, E–G). Moreover, the intracellular level of  myo-inositol-1-phosphate (IP1), an indicator 
of  IP3 generation (39), was also significantly repressed in XLKO cells (Supplemental Figure 2B).
PKC activation induces FGF23 production. Because IP3/PKC, but not cAMP, signaling was diminished 
upon XLαs ablation, we then examined whether activation of  PKC could rescue FGF23 expression in 
XLKO Ocy454 cells. Treatment with phorbol 12-myristate 13-acetate (PMA), a potent PKC activator, 
resulted in elevated FGF23 mRNA levels in both control (3.1-fold) and XLKO cells (7.3-fold), compared 
with vehicle-treated cells (Figure 4A). To further confirm the effect of  PKC signaling on FGF23 production 
in vivo, we injected P9 WT and XLKO pups i.p. with saline (as control) or PMA (500 ng/g body weight) 
Figure 2. Injection of recombinant FGF23 rescues the disrupted mineral ion levels in XLKO mice. (A) Serum phosphate 
levels and (B) ionized calcium levels of WT and XLKO littermates injected with saline (vehicle) or a stable FGF23 analog 
for 4 days (n = 9–14 per group). (C and D) mRNA levels of (C) Cyp27b1 and (D) Cyp24a1 in kidneys from WT and KO pups 
injected with saline or FGF23 (n = 8 per group). Data are shown as mean ± SEM. *P < 0.05; **P < 0.01, and NS, calculated 
by 1-way ANOVA followed by Tukey’s multiple-comparisons test.
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and analyzed the mice after 24 hours. Skeletal FGF23 mRNA levels, as well as serum FGF23 levels, were 
significantly increased in both WT and XLKO mice upon PMA injection, concurrently with a significant 
reduction in serum phosphate levels (Figure 4, B–D). Taken together, these results strongly suggested that 
activation of  PKC stimulates FGF23 production.
Constitutively active Gαq/PKC signaling stimulates FGF23 production. One of  the most important stimulators 
of  PKC is the Gq/11 signaling pathway, which can be triggered by multiple GPCRs (40, 41). Because stimu-
lation of  PKC signaling by PMA stimulated FGF23 production in vitro and in vivo, we addressed whether 
activation of  Gq/11 signaling also leads to FGF23 production in osteoblasts and osteocytes. Rosa26-floxed 
stop-GNAQQ209L (GNAQQ209L) mice (42), which drive expression of  a constitutively active Gqα mutant in cells 
that undergo Cre-mediated recombination, were crossed with osteocalcin-Cre–transgenic (Ocn-Cre–transgen-
ic) mice, which express Cre recombinase in osteoblasts and their descendants. Serum C-terminal FGF23 levels, 
as well as skeletal FGF23 mRNA expression, were dramatically increased in P10 GNAQQ209L Ocn-Cre mice 
(Figure 5, A and B), while the intact levels were only moderately increased (Figure 5C), indicating that the 
majority of  overproduced FGF23 in the double-transgenic mice was coupled with increased FGF23 cleavage. 
Figure 3. XLKO bones and XLKO cells show diminished PKC levels without impairment of the PTH/cAMP 
pathway. (A) Serum C-terminal FGF23 and (B) skeletal mRNA FGF23 levels upon 2-hour PTH treatment. 
**P < 0.01, ***P < 0.001, and NS, calculated by Welch’s t test (2 tailed) followed by Bonferroni’s correction. 
(C) Western blot analysis of PKCα and PKCδ using femur lysates from P10 WT and XLKO pups. Tubulin was 
used as a loading control. (D) Densitometric analysis of the relative abundance of PKCα and PKCδ. Data are 
shown as mean ± SEM of 7 or 8 mice from each group. *P < 0.05, and **P < 0.01. (E) FGF23 mRNA expres-
sion in control and XLKO Ocy454 cells. (F) PKCα and PKCδ protein levels were detected by using Western 
blot in control and XLKO Ocy454 cells. (G) Densitometric analysis of data represented in F relative to tubu-
lin. Data are shown as mean ± SEM of 3 independent experiments. **P < 0.01. (D, E, and G) Significance 
between 2 groups was defined by 2-tailed Student’s t test.
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In fact, phosphate levels were not changed in GNAQQ209L Ocn-Cre mice (Figure 5D). We also crossed 
GNAQQ209L with dentin matrix phosphoprotein 1–Cre (Dmp-Cre) mice, in which Cre is expressed in mature 
osteoblasts and osteocytes, and found a similar but milder increase of  FGF23 production in GNAQQ209L 
Dmp1-Cre mice (Figure 5, E–G); however, phosphate remained unchanged between control and dou-
ble-transgenic mice (Figure 5H). We also analyzed serum C-terminal and skeletal FGF23 mRNA levels in 
2-month-old control and GNAQQ209L Dmp1-Cre mice and found that FGF23 production remained elevated 
in double-transgenic mice (Supplemental Figure 3, A and B). Taken together, these results strongly suggested 
that Gq/11 signaling is able to promote FGF23 production.
Because adult XLKO mice, unlike their early postnatal counterparts, displayed only a modest reduc-
tion of  FGF23 levels, and because constitutively active Gq/11 signaling promoted FGF23 synthesis both 
early postnatally and in adulthood, we compared mRNA levels of  XLαs, as well as Gqα and G11α, in P10 
and 8-week-old mouse femurs. qRT-PCR experiments revealed that the level of  XLαs in 8-week-old femur 
was only 1.8% ± 0.9% of  that in P10 femur, suggesting a dramatic decline of  XLαs expression with age. In 
contrast, the levels of  Gqα and G11α at 8 weeks were 63.1% ± 1.8% and 75.3% ± 2.4% of  the levels at P10, 
respectively (Supplemental Figure 3C).
The Gq/11/PKC signaling–induced FGF23 production is dependent on MAPK signaling. Both control and 
XLKO Ocy454 clonal cells transduced with adenovirus encoding XLαs showed marked elevation of  
FGF23 mRNA levels compared with cells transduced with adenoviral YFP used as control (Figure 6A, 
Supplemental Figure 4A). In addition, treatment of  these cells individually with isozyme nonselec-
tive PKC inhibitors (bisindolylmaleimide I [Bisindol], Ro-31-8220, or Ro-32-0432) significantly, albeit 
incompletely, blocked the XLαs overexpression–induced FGF23 production, demonstrating that XLαs 
regulates FGF23 production via PKC signaling (Figure 6B). The rise of  FGF23 mRNA levels by PMA 
treatment was completely blocked by treatment with these PKC inhibitors (Figure 6C). Similar results 
were obtained with Saos-2 cells, a human osteosarcoma cell line (Supplemental Figure 4B). PMA also 
stimulates production of  inflammation mediators, such as IL-6, which has been recently shown to 
Figure 4. PKC activation stimulates FGF23 production and restores the FGF23 levels in XLKO. (A) Control and XLKO 
Ocy454 cells were treated with PMA or vehicle (DMSO) for 6 hours. mRNA levels of FGF23 were assessed by qRT-PCR. Data 
represent mean ± SEM of values obtained from control and XLKO clones. aP < 0.05 vs. DMSO-treated control cells; bP < 0.05 
vs. DMSO-treated KO cells; cP < 0.05 vs. PMA-treated control cells. (B–D) WT and XLKO mice were injected i.p. with saline 
or PMA. (B) Femur FGF23 mRNA (n = 8 per group), (C) serum FGF23 (C-terminal assay; n = 11–15 per group), and (D) serum 
phosphate (n = 11–15 per group) levels were examined 24 hours after the injection. aP < 0.05 vs. saline-injected WT mice; bP < 
0.05 vs. saline-injected XLKO mice; cP < 0.05 vs. PMA-injected WT mice. *P < 0.05 vs. saline. Significance was determined by 
unpaired, 2-tailed Student’s t test.
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directly stimulate FGF23 production (43). PMA treatment of  Ocy454 cells significantly increased IL-6 
mRNA levels, and 2 of  the PKC inhibitors, Bisindol and Ro-32-0432, repressed PMA-stimulated IL-6 
induction (Figure 6D). However, Ro-31-8220, which could inhibit both PMA- and XLαs overexpres-
sion–induced FGF23 production, further increased the PMA-induced IL-6 mRNA level rather than 
repressing it (Figure 6D), strongly suggesting that PKC activation–mediated FGF23 production was 
not associated with IL-6 expression. The level of  ERK1/2 phosphorylation (p-ERK1/2) was also dra-
matically repressed in XLKO bones and in XLKO Ocy454 cells (Figure 6, E–H). PMA treatment also 
stimulated p-ERK1/2 levels markedly in control and XLKO Ocy454 cells (Figure 6, I and J). In addi-
tion, MEK inhibitor U0126 inhibited PMA-induced FGF23 elevation, suggesting that MAPK signaling 
is downstream of  PKC activation and plays an important role in mediating PKC activation–mediated 
FGF23 production (Figure 6K). Because FGFR1 signaling is a known mediator of  FGF23 production 
in bone, we also examined FGFR1 expression in P10 femurs and clonal Ocy454 cells and revealed 
significantly reduced FGFR1 mRNA levels in XLKO bones and cells (Supplemental Figure 5, A and 
B). We then induced FGFR1 transcription in Ocy454 cells through the CRISPR/Cas9 synergistic acti-
vation mediator (44), using several activator sgRNAs. Two of  the FGFR1 promoter–targeting sgRNAs 
(activator 1 and activator 2) resulted in significantly increased FGFR1 mRNA expression in WT and 
XLKO cells (Supplemental Figure 5C). These sgRNAs also raised FGF23 mRNA levels in both WT 
and XLKO cells and fully rescued the reduced FGF23 levels in XLKO cells (Supplemental Figure 5D). 
Nevertheless, FGFR1 mRNA expression levels were not altered in femurs from GNAQQ209L Ocn-Cre or 
GNAQQ209L Dmp1-Cre double-mutant mice (Supplemental Figure 5, E and F), which, as shown above, 
displayed elevated serum and skeletal mRNA levels of  FGF23. These results suggested that the Gq/11/
PKC activation–induced FGF23 synthesis may not involve elevation of  FGFR1 levels.
Skeletal PKC activity and MAPK signaling are elevated in a mouse model of  XLH. XLH is the most com-
mon form of  inherited rickets, which is driven by hypophosphatemia caused by excess FGF23 produc-
tion (45). Hyp mice, a murine model of  XLH, also have dramatically elevated FGF23 levels. To assess 
the level of  overall PKC activity in Hyp mice bones, we used Western blot analysis using an antibody 
recognizing proteins phosphorylated at PKC consensus sites. Our results showed significantly increased 
Figure 5. Constitutively active Gqα signaling induces FGF23 production in mice. (A) Serum C-terminal FGF23, (B) 
skeletal FGF23 mRNA, (C) intact FGF23, and (D) phosphate levels in GNAQQ209L Ocn-Cre mice and control littermates. (E) 
Serum C-terminal FGF23, (F) skeletal FGF23 mRNA, (G) intact FGF23, and (H) phosphate levels in GNAQQ209L Dmp1-Cre 
mice and control littermates. *P < 0.05, **P < 0.01, ***P < 0.001, and NS, calculated by 2-tailed Student’s t test.
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levels of  some of  these PKC-phosphorylated proteins in Hyp bones (Figure 7, A and B), consistent with 
enhanced PKC activity. The level of  p-ERK1/2 in Hyp bones was also significantly increased (Figure 
7, A and C). A single injection of  P10 WT and Hyp littermates with the PKC inhibitor Ro-32-0432 
revealed, 24 hours later, a mild trend toward lower serum FGF23 and higher serum phosphate levels 
in Hyp mice compared with vehicle-injected mice (Supplemental Figure 6, A and B). Because ablation 
of  XLαs reduced PKC activation and FGF23 production in vivo, we then intercrossed XLKO and Hyp 
mice. At P10, XLKO/Hyp double-mutant mice were still hypophosphatemic and displayed increased 
FGF23 levels compared with WT mice. However, compared with Hyp mice, the XLKO/Hyp dou-
ble mutants showed a moderate but significant decrease in C-terminal FGF23 levels, as well as intact 
FGF23 levels (Figure 7, D and E). Likewise, serum phosphate levels were significantly increased in the 
XLKO/Hyp double mutants compared with Hyp littermates (Figure 7F). These results suggested that 
suppression of  XLαs/PKC signaling could alleviate the biochemical phenotype of  Hyp mice.
Figure 6. PKC activation mediates FGF23 production by promoting MAPK signaling. (A) FGF23 mRNA expression in YFP- and XLαs-overexpressing 
Ocy454 cells. **P < 0.01, and ***P < 0.001, determined by Welch’s t test (2 tailed) followed by Bonferroni’s correction. (B) FGF23 mRNA expression in 
control or XLαs adenovirus–infected Ocy454 cells treated with PKC inhibitors, bisindolylmaleimide I (Bisindol), Ro-31-8220, or Ro-32-0432. Data are shown 
as mean ± SEM of 3 independent experiments. *P < 0.05 vs. control group; #P < 0.05 vs. XLαs-overexpressing Ocy454 cells. (C and D) Ocy454 cells were 
treated with PMA, with PKC inhibitors. qRT-PCR analysis of (C) FGF23 and (D) IL-6 mRNA after 6 hours of treatment. Data are shown as mean ± SEM of 4 
independent experiments. *P < 0.05 vs. control group; #P < 0.05 vs. PMA-treated group. (B–D) Significance was calculated by 1-way ANOVA followed by 
Tukey’s multiple-comparisons test. (E) Representative Western blot of phosphorylated ERK1/2 (p-ERK) and total (phosphorylated and nonphosphorylat-
ed) ERK1/2 (total ERK) in femur bone lysate samples from P10 XLKO (KO) and WT mice. Loading control: tubulin. (F) Densitometric analysis of the ratio of 
p-ERK to total ERK in KO and WT femurs. Data are shown as mean ± SEM of 7 mice from each group. (G) Western blot analysis of p-ERK, ERK, and tubulin 
levels in control and XLKO Ocy454 cells. (H) Densitometric analysis of p-ERK/total ERK ratio represented in G. Data are shown as mean ± SEM from 3 inde-
pendent experiments. (F and H) *P < 0.05, **P < 0.01 by 2-tailed Student’s t test. (I) Western blot analysis of p-ERK, ERK, and tubulin in XLKO and control 
cells treated with PMA or vehicle. (J) Densitometric analysis of p-ERK/ERK ratio represented in I. aP < 0.05 vs. vehicle-treated control cells; bP < 0.05 vs. 
vehicle-treated KO cells; cP < 0.05 vs. PMA-treated control cells. (K) FGF23 mRNA levels in Ocy454 cells treated with PMA, with or without MEK inhibitor 
U0126. Data are shown as mean ± SEM of 3 independent experiments. *P < 0.05 vs. control group; #P < 0.05 vs. PMA-treated group. Statistical differences 
in J and K were assessed with 1-way ANOVA followed by Tukey’s test.
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Discussion
Our study shows that the unique Gα subunit XLαs, which, in spite of being mostly identical to Gsα, promotes 
IP3/PKC signaling, is required for FGF23 production in early postnatal mice. Our investigations also revealed 
that the IP3/PKC signaling pathway, presumably downstream of an as-yet-unidentified GPCR, is an import-
ant mediator of skeletal FGF23 production through a mechanism dependent on MAPK signaling (Figure 8).
Excess FGF23 production was observed in response to the activation of  PKC, stimulated by XLαs over-
expression, phorbol esters, or constitutive Gq/11 activation. PKC activation has been shown to promote MAPK 
signaling in osteoblastic cells (46). We also observed elevated ERK1/2 phosphorylation upon PMA treatment 
of  Ocy454 cells, and the baseline level of  ERK1/2 phosphorylation was diminished in XLKO bones, which 
concurrently had reduced PKCα and PKCδ levels. Taken together with the finding that MAPK inhibitor 
U0126 blocked the PKC activation–induced FGF23 production, it appears that PKC mediates FGF23 pro-
duction by promoting, at least partly, the MAPK signaling pathway. In contrast, our findings from PKC inhib-
itor experiments strongly suggest that PKC-mediated FGF23 production is independent of  IL-6.
PKC inhibitors blunted the effect of  XLαs overexpression but entirely abrogated the effect of  PMA 
treatment on FGF23 mRNA levels in Ocy454 cells. This finding may reflect the possibility that the 
XLαs overexpression caused a much stronger PKC activation than did the PMA treatment. Alterna-
tively, XLαs overexpression may have promoted FGF23 production additionally through the cAMP 
signaling pathway because it can result in significantly increased basal cAMP production (47, 48). 
However, we found that PMA treatment did not fully restore the levels of  ERK1/2 phosphorylation 
in XLKO cells, suggesting that the action of  XLαs entails additional pathways that may converge on 
MAPK signaling. One of  those may be FGFR signaling. Fgfr1 mRNA levels were diminished in XLKO 
bones, and overexpression of  Fgfr1, which presumably enhanced MAPK signaling, could override the 
suppressed FGF23 synthesis caused by XLαs deficiency. This finding may suggest that the presumably 
diminished FGFR1 levels contribute to the low FGF23 levels in XLKO cells. Future studies are needed 
to fully understand the Gq/IP3/PKC pathway–independent role of  XLαs in the regulation of  FGFR1/
MAPK signaling and FGF23 synthesis. Nonetheless, it is important to note that our mice in which Gq/
PKC signaling was constitutively activated in bone showed a pronounced FGF23 overproduction in the 
Figure 7. Elevated PKC activity contributes to the elevated FGF23 in Hyp mice. (A) Western blot analysis of phosphorylated 
PKC (p-PKC) substrates, p-ERK, and total ERK in WT and Hyp mice. (B) Densitometric analysis of the relative abundance of 
p-PKC substrates. (C) Densitometric analysis of p-ERK/total ERK ratio represented in A. Data are shown as mean ± SEM of 7 
or 8 mice from each group. *P < 0.05, calculated by unpaired, 2-tailed Student’s t test. (D) Serum C-terminal FGF23, (E) intact 
FGF23, and (F) phosphate levels in Hyp and XLKO intercross littermates. *P < 0.05, and ***P < 0.001, determined by Welch’s 
t test (2 tailed) followed by Bonferroni’s correction.
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absence of  elevated Fgfr1 expression. Thus, it appears that the IP3/PKC signaling–mediated FGF23 
production does not require elevation of  FGFR1 levels.
FGF23 increases urinary phosphate excretion by repressing the activity of  NaPi-2a and NaPi-2c 
cotransporters to reduce renal phosphate reabsorption to maintain systemic phosphate homeostasis. In 
mice expressing the constitutively active Gqα mutant in bone cells, serum phosphate levels were not altered, 
despite the modestly increased levels of  serum intact FGF23 in the mutant mice. It is possible that the 
urinary phosphate excretion was increased in those mice, but our assay was unable to detect the change 
in serum phosphate. In contrast, the PMA-injected mice displayed low serum phosphate compared with 
vehicle-injected mice. The latter finding may reflect a direct effect of  PMA on the renal proximal tubules 
because PKC activation promotes renal phosphate excretion (49).
We detected increased levels of  phosphorylated proteins by PKC in Hyp bones, suggesting elevated 
PKC activity in this mouse model of  XLH. Consistent with our finding, a microarray analysis of  Hyp 
bones revealed 41 genes upregulated by more than 2-fold (50), and a number of  them are positively regu-
lated by PKC activation in bone or in other cell types, including Egr2, Eln, Prkg2, Cyp11a1, Lipg, Gem, and 
F3 (51–54). The underlying cause of  elevated skeletal PKC activity in XLH is currently unknown. None-
theless, our results obtained from intercrosses between Hyp and XLKO, as well as from the injection of  a 
PKC inhibitor into Hyp and control mice, suggest that the increased PKC activation in XLH contributes to 
the elevated FGF23 production.
Based on our PTH injection experiments, the novel FGF23 synthesis mechanism involving G 
protein/PKC activation does not mediate the action of  PTH. This is consistent with previous studies 
showing that PTH-induced FGF23 production occurs via cAMP-mediated mechanisms (15–18, 55). In 
contrast, 1,25(OH)2D- and phosphate-induced FGF23 production may depend, at least partly, on the G 
protein/PKC pathway, given that the significantly elevated 1,25(OH)2D and phosphate levels in XLKO 
pups were insufficient to maintain the normal level of  FGF23. Likewise, XLKO pups have been report-
ed to have serum iron deficiency (38), and therefore, it appears that lack of  XLαs also impedes the effect 
of  iron deficiency on FGF23 production. Consistent with these conclusions, MAPK signaling has been 
implicated in FGF23 synthesis in response to both iron deficiency and phosphate (56–58). Nonetheless, 
further studies are needed to address whether XLαs or IP3/PKC signaling modulates the actions of  
these major FGF23 regulators.
Adult XLKO mice displayed only mildly reduced serum FGF23 levels as opposed to P10 XLKO, 
which had significantly decreased FGF23 production. The outcome of  XLαs ablation on FGF23 lev-
els may be masked by the systemic alterations previously documented in adult XLKO mice, such as 
increased levels of  circulating catecholamines (59). It is also possible, however, that XLαs is not expressed 
at significant levels in adult osteocytes/osteoblasts and, therefore, has a minor role in FGF23 synthesis. 
XLαs protein or mRNA is readily detectable in adult mouse bone and adult human bone marrow stromal 
cells (26, 28), but we found a dramatic decline of  XLαs mRNA levels from P10 to age 8 weeks in mouse 
femurs, supporting the latter possibility. In contrast, the levels of  Gqα or G11α did not change as dramat-
ically with age, making it plausible that the Gq family of  α subunits take over XLαs’s role as a mediator 
of  FGF23 production in adulthood.
Figure 8. A model of XLαs function in FGF23 production. In bone cells, XLαs and Gq/11α promote FGF23 production, 
presumably in response to the activation of an as-yet-unknown GPCR. XLαs or Gq/11α activates PKC and stimulates 
the MAPK/ERK1/2 pathway, which has also been implicated in the FGF23 production regulated by FGFR1 signaling, 
iron deficiency, and phosphate. The action of PTH on FGF23 synthesis involves Gsα/cAMP signaling and appears to be 
independent from the pathway mediated by G protein–IP3/PKC. 
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Genetic mutations affecting the paternal GNAS allele result in complete loss of  XLαs in most tissues 
because of  the genomic imprinting of  its promoter. Thus, our findings predict that children with paternal 
GNAS disruption, i.e., pseudo-pseudohypoparathyroidism, can have reduced FGF23 production and resul-
tant hyperphosphatemia. Accordingly, certain pediatric patients carrying such genetic defects have been 
reported to have normal or elevated serum phosphate with mildly elevated PTH levels (29–35). However, it 
should be noted that patients with paternal GNAS mutations also have Gsα haploinsufficiency, which may 
contribute to those findings or could mask the phenotypic expression of  XLαs deficiency alone.
In summary, we discovered a potentially novel mechanism of  FGF23 synthesis involving an as-yet-un-
identified GPCR that signals via the IP3/PKC pathway feeding into MAPK signaling (Figure 8). Further 
elucidation of  the underlying mechanisms may identify novel drug targets for treating the diseases caused 
or affected by dysregulated FGF23 production. As such, it will be important to identify the GPCR(s) that 
couples to XLαs and/or Gq/11α in this context. Targeting that receptor by an agonist or an antagonist may 
allow FGF23 levels to be fine-tuned as needed.
Methods
Mice. XLKO mice were generated by disrupting the first exon of  XLαs on the paternal allele, thus resulting 
in the global ablation of  this protein (60). These mice were maintained on a CD1 genetic background. 
GNAQQ209L-transgenic mice were generated and described previously (42); they were maintained on a 
C57BL/6 background. Ocn-Cre, Dmp1-Cre, and Hyp mice were also on a C57BL/6 background and pur-
chased from The Jackson Laboratory. Both male and female Hyp mice were included in the analyses, 
which were performed on P10.
Chemical compounds. Recombinant human FGF23 containing naturally occurring pathogenic Arg-to-
Gln mutations at its 176RHTR179 proteolytic cleavage site, FGF23R176Q/R179Q (aa 25–251), was generated 
in-house (61). Synthetic human PTH (aa 1–34) was synthesized by The Peptide/Protein Core Facility 
at Massachusetts General Hospital. The broad-range PKC inhibitor Bisindol was purchased from Milli-
poreSigma; another 2 PKC inhibitors, Ro-32-0432 and Ro-31-8220, were from Santa Cruz Biotechnolo-
gy. MEK inhibitor U0126 was purchased from Cell Signaling Technology. PMA, forskolin, and all other 
reagents were purchased from MilliporeSigma.
Measurement of  serum biochemistries. Serum concentrations of  phosphate, Ca2+, PTH, and 1,25(OH)2D 
were examined by using blood samples obtained from the carotid artery, as described previously (24). 
C-terminal and intact FGF23 concentrations were measured with the Mouse/Rat FGF-23 (C-Term) and 
Mouse/Rat FGF-23 (Intact) ELISA kits (Quidel).
Cell culture. The Ocy454 cells, which were previously described (37), were maintained in α–minimum 
essential medium (α-MEM, Gibco) with 10% FBS at 33°C and differentiated into osteocyte-like cells by 
growing at 37°C for 1 week (37, 62). XLKO and control clonal Ocy454 cells were generated previously (38) 
and used here for protein and mRNA analyses. Saos-2 cells were obtained from ATCC (ATCC HTB-85) 
and cultured at 37°C in McCoy’s 5a medium (Gibco) supplemented with 15% FBS. To test the effects of  
PMA and different inhibitors, the cell culture was changed to α-MEM with 2% FBS overnight before treat-
ing with 1 μM PMA, with or without inhibitor (10 μM Bisindol, 10 μM Ro-32-0432, 10 μM Ro-31-8220, or 
10 μM U0126) for 6 hours.
Generation of  FGFR1 transcriptionally activated Ocy454 cells by CRISPR/sgRNA–directed synergistic activation 
mediator. Four sgRNAs targeting the Fgfr1 gene were designed through the Synergistic Activation Medi-
ator Cas9 activator design tool (http://sam.genome-engineering.org/database/) and subcloned into the 
lenti sgRNA(MS2)_zeo vector (Addgene). Based on the efficiency of  Fgfr1 activation, 2 activation guides, 
FGFR1 activator 1 and activator 2, were selected for further analysis. Viral packaging was performed in 
293T cells (ATCC) using standard protocols by cotransfection of  the lentiviral plasmid along with psPAX2 
(Addgene) and MD2.G (Addgene) using PolyJet DNA Transfection Reagent (SignaGen Laboratories). 
XLKO and control Ocy454 cells were transduced with lentiviral dCas9-VP64, MS2-P65-HSF1, together 
with lentiviral FGFR1 activator 1, activator 2, or sgRNA(MS2)_zeo, and then selected with blasticidin (5 
μg/mL), hygromycin (100 μg/mL), and zeocin (200 μg/mL) to enrich for cells stably expressing the lentivi-
rus. Cells were maintained in the selection medium throughout the duration of  the experiment.
cDNA synthesis and qRT-PCR analysis. Total RNA isolated from kidneys and femurs of  P10 mice, as well 
as that from Ocy454 and Saos-2 cells, was prepared with the RNeasy Plus Mini Kit (Qiagen), and cDNA 
was synthesized with the ProtoScript II First Strand cDNA Synthesis Kit (New England BioLabs), as 
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previously described (63). qRT-PCR analysis on FGF23 was tested by using FGF23-FAM and Actb-VIC 
TaqMan primers and TaqMan Fast Advanced Master Mix (Applied Biosystems). qRT-PCR analysis on 
all other genes was performed with specific primers (Supplemental Table 1) and PowerUp SYBR Green 
Master Mix (Applied Biosystems) with Actb as a reference gene.
Cell/tissue lysis and Western blot analysis. Cells and femur tissues were lysed by using HNTG lysis 
buffer (20 mm HEPES, pH 7.4; 150 mm NaCl; 10% glycerol; 1% Triton X-100, 1.5 mm MgCl2; 1.0 mm 
EGTA) containing Complete Protease inhibitor mixture tablets (Roche). Lysates were resolved by 10% 
SDS-PAGE and transferred to nitrocellulose membranes (Bio-Rad). Western blots were then incubated 
with specific antibodies. Antibody against p-ERK was purchased from MilliporeSigma (catalog M8159) 
and tubulin antibody from Abcam (catalog ab6046). Antibodies against phospho-PKC substrates (cat-
alog 2261S), total ERK (catalog 9102S), PKCα (catalog 9960S), and PKCδ (catalog 9960S) were from 
Cell Signaling Technology. Gsα antibody, which recognizes both Gsα and XLαs, was purchased from 
MilliporeSigma (catalog 06-237).
Histology, immunohistochemistry, and immunofluorescence staining. Kidney sections from P10 XLKO and 
WT mice were stained with Npt2a antibody (64) at 4°C overnight and then stained with Alexa Fluor 568–
conjugated donkey anti-rabbit antibody (Life Technologies) at room temperature for 1 hour. Immunoreac-
tivity was visualized and analyzed with a Nikon Eclipse Ni microscope and SPOT Microscope Imaging 
Software or with a Zeiss LSM 510 confocal microscope and Zeiss Zen software.
Isolation of  renal brush border membranes. Brush border membrane portions were prepared from the kid-
neys of  P10 WT and XLKO mice as described previously (65) with minor modifications. Isolated brush 
border membrane proteins were lysed in a Tris-buffered solution containing 150 mM NaCl and 1% Triton 
X-100. Measurement of  protein concentrations in the samples with antibodies specific for Npt2a (64) and 
Villin (Santa Cruz Biotechnology , sc-58897) were performed as described previously (24).
IP1 and cAMP assays. The amount of  IP1, a downstream metabolite of  IP3, in control and XLKO Ocy454 
cells was tested using the IP1 HTRF assay kit (Cisbio) as previously described (25). For cAMP assay, con-
fluent control and XLKO Ocy454 cells in 96-well plates were treated with different concentrations of  PTH, 
forskolin, or vehicle, with 2 mM 3-isobutyl-1-methylxanthine for 30 minutes at room temperature, before 
lysing the cells for RIA measurement.
Recombinant FGF23R176Q/R179Q, PTH, PMA, and Ro-32-0432 injections. The recombinant FGF23 com-
pound (61, 66) or vehicle was injected i.p. into WT and XLKO mice (250 ng/g body weight) from P6 to 
P10 at 12-hour intervals (67). The mice were sacrificed 12 hours after the last injection, and blood and 
kidneys were collected for analysis. To test PTH-induced FGF23 production in WT and XLKO mice, 
mice were injected subcutaneously with either PTH (aa 1–34) (50 nmol/kg) or vehicle (10 mm citric acid, 
150 mm NaCl, 0.05% Tween 80, pH 5.0) for 2 hours before analysis (55). To test the effect of  PMA on 
FGF23 production, WT and XLKO mice were injected i.p. with vehicle or PMA (500 ng/g body weight) 
(68, 69) at P9 and sacrificed 24 hours later. Blood and femurs were collected to measure serum FGF23 
and phosphate levels, as well as bone FGF23 mRNA levels. PKC inhibitor Ro-32-0432 (6 mg/kg body 
weight) or vehicle was i.p. injected into P9 WT and Hyp mice for 24 hours. Blood was collected to mea-
sure serum FGF23 and phosphate levels.
Statistics. All data are presented as mean ± SEM as indicated in the figure legends. The unpaired, 
2-tailed Student’s t test was used to determine the significance of  differences between 2 groups, and 
1-way ANOVA followed by Tukey’s multiple-comparisons test was used to determine statistical signif-
icance among 3 or more groups. Welch’s t test (2 tailed) was used for multiple comparisons involving 
groups with unequal variances, followed by Bonferroni’s correction (that is, P values were multiplied 
by the number of  comparisons). P values smaller than 0.05 (*P < 0.05, **P < 0.01, and ***P < 0.001) 
were considered significant.
Study approval. All the animal experiments were conducted in accordance with the accepted standards 
of  the Institutional Animal Care and Use Committee, and the studies were approved by the Massachusetts 
General Hospital (MGH) Subcommittee on Research Animal Care.
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